Bespoke Patches

With decades of pioneering proteomics expertise, SomaLogic delivers a comprehensive protein detection technology to expose early biologic signs that a patient may be headed for a severe health event, revealing whether existing treatments are adequately reducing risk or if adaptations are needed. Because proteins are constantly changing, they provide better and more actionable insights on patient health risks and propensity for disease. Unlike SomaLogic solutions, most current tools are not prognostic in nature and can’t be used to determine future health risk–they’re mostly used to confirm whether a person has elevated risk. These approaches are also not responsive to change over time, which makes it difficult to understand if existing treatments are effective and to track disease trajectory.

CancerIQ is solving three main access problems related to starting, running and growing a cancer genetics program: Identification. Because gathering family history can be time-consuming and laborious, providers often skip this step altogether, leaving patient genetic risk remains unknown. CancerIQ’s platform digitally collects family and lifestyle history and automatically identifies and flags patients who qualify for genetic testing based on the newest industry guidelines. Clinical guidance. It’s difficult to interpret genetic tests and personalize patient care because most providers do not have extensive genetics training and guidelines change on a regular basis. CancerIQ automatically generates care plan recommendations and guides shared decision-making and patient activation at the point of care. Follow-through. Without the proper education and engagement, patients don’t adhere to personalized care recommendations and programs don’t generate the clinical and financial return on investment they expect. CancerIQ provides the tools and technology that health systems need in order to engage and manage high-risk patients over time and improve long-term outcomes.

Precision medicine represents a transformative approach to healthcare delivery that tailors medical decisions, practices, and treatments to individual patients based on their genetic, environmental, and lifestyle factors. Digital solutions in this space integrate genomic analysis, clinical decision support, and advanced analytics to enable personalized care delivery at scale.

Conversational AI is an advanced technology that allows machines to understand, process, and respond to human language in a way that is both contextually relevant and interactive. Within the healthcare sector, this technology is increasingly deployed to automate routine tasks and deliver a more robust and personalized patient experience. Conversational AI leverages a combination of machine learning, natural language processing, and occasionally deep learning to interpret and respond to user inputs, with a conversational user interface that mimics human interaction. Digital health companies deploy conversational AI through chatbots, voice assistants, messaging apps, or any other type of platform where natural language interactions occur.

The Digital Front Door (DFD) methodology has emerged as a pivotal element in enhancing patient engagement, streamlining operations, and ensuring a competitive advantage. In a 2022 KLAS Top of Mind Research Report, 55% of healthcare leaders stated that their organization uses some form of DFD technology. The organizations that didn’t yet have one said it was on their radar for later implementation.

Jen Magaziner, VP, Digital Health at Boston Children's Hospital and Sonia Singh, Chief Insights Officer at AVIA discuss the latest on accelerating innovation at Boston Children's Hospital in AVIA's "Voices of the AVIA Network" series.